American Renal Associates Holdings, Inc (NYSE:ARA) will announce its earnings results after the market closes on Wednesday, November 8th. Analysts expect the company to announce earnings of $0.16 per share for the quarter.

American Renal Associates Holdings (NYSE:ARA) last issued its quarterly earnings data on Tuesday, August 8th. The company reported $0.16 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.12 by $0.04. American Renal Associates Holdings had a positive return on equity of 18.25% and a negative net margin of 1.54%. The firm had revenue of $185.99 million during the quarter, compared to the consensus estimate of $188.23 million. The company’s revenue was up .2% on a year-over-year basis. On average, analysts expect American Renal Associates Holdings to post $0.54 EPS for the current fiscal year and $0.71 EPS for the next fiscal year.

American Renal Associates Holdings, Inc (NYSE ARA) opened at 12.13 on Wednesday. The firm has a 50-day moving average price of $13.96 and a 200 day moving average price of $13.98. The company’s market cap is $379.49 million. American Renal Associates Holdings, Inc has a 12 month low of $12.08 and a 12 month high of $25.42.

WARNING: “American Renal Associates Holdings, Inc (ARA) Scheduled to Post Quarterly Earnings on Wednesday” was reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this piece on another site, it was stolen and republished in violation of United States and international copyright law. The legal version of this piece can be accessed at https://theolympiareport.com/2017/11/01/american-renal-associates-holdings-inc-ara-scheduled-to-post-quarterly-earnings-on-wednesday.html.

A number of equities research analysts recently issued reports on the company. SunTrust Banks, Inc. set a $18.00 price target on American Renal Associates Holdings and gave the stock a “buy” rating in a research report on Sunday, October 15th. Zacks Investment Research downgraded American Renal Associates Holdings from a “buy” rating to a “hold” rating in a research report on Wednesday, July 12th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company’s stock. American Renal Associates Holdings presently has an average rating of “Hold” and an average price target of $20.33.

An institutional investor recently raised its position in American Renal Associates Holdings stock. The Manufacturers Life Insurance Company raised its holdings in American Renal Associates Holdings, Inc (NYSE:ARA) by 19.7% during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 8,778 shares of the company’s stock after purchasing an additional 1,443 shares during the quarter. The Manufacturers Life Insurance Company ‘s holdings in American Renal Associates Holdings were worth $162,000 as of its most recent SEC filing. Institutional investors own 90.57% of the company’s stock.

American Renal Associates Holdings Company Profile

American Renal Associates Holdings, Inc is a dialysis service provider in the United States focused on joint venture (JV) partnerships with physicians. As of December 31, 2016, the Company owned and operated 214 dialysis clinics in partnership with 379 nephrologist partners treating over 14,000 patients in 25 states and the District of Columbia.

Earnings History for American Renal Associates Holdings (NYSE:ARA)

Receive News & Ratings for American Renal Associates Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates Holdings Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.